Navigation Links
Perrigo Company Confirms FDA Tentative Approval for Clobetasol Propionate Emulsion Foam

ALLEGAN, Mich., Oct. 6, 2011 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO;TASE) announced that it received tentative approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clobetasol Propionate Emulsion Foam, 0.05%. Perrigo believes it is first-to-file on this product.

On July 12, 2010, Stiefel Research Australia Pty. Ltd. filed a patent infringement suit in the United States District Court for the District of Delaware to prevent Perrigo from commercializing this product.  This action, which is still pending, formally initiated the process under the Hatch-Waxman Act.

The product is the AB-rated equivalent to Stiefel Laboratories' Olux® -E Foam, 0.05%, a topical corticosteroid indicated for the treatment of moderate to severe dermatosis of the scalp. Sales for the brand were approximately $40 million, according to Wolters Kluwer data for the twelve months ending September 2011.

Perrigo's Chairman and CEO Joseph C. Papa stated, "This tentative approval reflects our strategy to be first to market with the important products that make quality healthcare more affordable for our customers and drive value for our shareholders, it is also another example of the excellent partnership we have with Cobrek for developing foam products which is a key product category for our Rx business."

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, and active pharmaceutical ingredients (API). The Company is the world's largest manufacturer of OTC pharmaceutical products and infant formulas, both for the store brand market. The Company's primary markets and locations of manufacturing and logistics operations are the United States, Israel, Mexico, the United Kingdom and Australia. Visit Perrigo on the Internet (

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections.  While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 25, 2011, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Perrigo Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Perrigo to Host Analyst Day on October 5, 2011 at the TASE, Tel Aviv Stock Exchange in Tel Aviv, Israel
2. Perrigo to Host Analyst Day on September 27, 2011 at the NASDAQ MarketSite in Times Square
3. Perrigo Announces FDA Final Approval for Ketoconazole Foam, 2%
4. Perrigo Company Will Release Fourth Quarter Fiscal 2011 Results on August 16, 2011
5. Watson Enters into Agreement to Acquire Products Related to Perrigos Acquisition of Paddock Laboratories
6. Perrigo Closes Acquisition of Paddock Labs
7. Perrigo Receives FDA Approval to Market Coated Cinnamon Nicotine Gum
8. Perrigo Provides Update on Acquisition of Paddock Labs
9. Perrigo Announces Launch of the Generic Version of Nasacort® AQ
10. Perrigo Company to Present at the Goldman Sachs 32nd Annual Global Health Care Conference
11. Perrigos Partner Synthon Receives FDA Tentative Approval for Levocetirizine Solution - Generic Equivalent to Xyzal® Oral Solution
Post Your Comments:
(Date:11/27/2015)... Pays-Bas, November 27, 2015 ... traitement photodynamique au Bremachlorin contre le cancer avancé. ... consistant à combiner l,immunothérapie au traitement photodynamique au ... --> Une nouvelle approche consistant à ... le cancer avancé.    Clinical ...
(Date:11/27/2015)... DUBLIN , Nov. 27, 2015 Research ... of the "Global Intrauterine Devices Market 2015-2019" ... --> In this report, the author ... intrauterine devices market for 2015-2019. To calculate the market ... of following type of products: Hormonal IUDs and copper ...
(Date:11/26/2015)... , 26 november 2015 AAIPharma ... de geplande investering aan van ten minste ... laboratoria en het mondiale hoofdkantoor in ... zal resulteren in extra kantoorruimte en extra ... de groeiende behoeften van de farmaceutische en ...
Breaking Medicine Technology:
(Date:11/28/2015)... (PRWEB) , ... November 28, 2015 , ... Trying to ... has created the COUCH BUDDY. "I conceived of this design due to personal experience ... for couch users. It promotes relaxation and convenience, as well as increases support. It ...
(Date:11/27/2015)... ... ... According to an article published November 6th by The Telegraph, ... British Columbia suggested that laws requiring bicyclists to wear helmets may not actually decrease ... reason for the controversial conclusion is that, while helmets have certainly prevented a great ...
(Date:11/27/2015)... PA (PRWEB) , ... November 27, 2015 , ... ... how filthy the toilets were," said an inventor from Hillside, N.J. "Many people ... improved seat cover so that individuals will always be protected from germs." , ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... through sharing, the 2016 Building Better Radiology Marketing Programs meeting will ... on Sunday, March 6, 2016, at Caesars Palace in Las Vegas with a ...
(Date:11/27/2015)... ... November 27, 2015 , ... CBD College is proud to announce ... (CAAHEP) awarded accreditation to its Diagnostic Medical Sonography program. CBD College is honored to ... of twelve colleges and universities in the state of California make the cut. CBD ...
Breaking Medicine News(10 mins):